American International Group, Inc. Bei Gene, Ltd. Transaction History

American International Group, Inc.

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 14, 2022	BUY	$131.8 - $202.24 $13,180 - $20,224	100 Added 16.67%	700 $94,000
Q1 2021 May 07, 2021	BUY	$260.64 - $382.12 $156,384 - $229,272	600 New	600 $209,000
Q4 2020 Feb 12, 2021	SELL	$221.31 - $316.61 $1.29 Million - $1.84 Million	-5,822 Closed	0 $0
Q3 2020 Nov 04, 2020	BUY	$189.18 - $286.44 $41,619 - $63,016	220 Added 3.93%	5,822 $1.67 Million
Q2 2020 Aug 12, 2020	BUY	$123.9 - $195.41 $156,981 - $247,584	1,267 Added 29.23%	5,602 $1.06 Million
Q1 2020 May 04, 2020	BUY	$121.84 - $173.19 $36,552 - $51,957	300 Added 7.43%	4,335 $534,000
Q4 2019 Feb 05, 2020	BUY	$115.78 - $208.34 $16,672 - $30,000	144 Added 3.7%	4,035 $669,000
Q3 2019 Nov 08, 2019	BUY	$120.61 - $148.29 $44,022 - $54,125	365 Added 10.35%	3,891 $476,000
Q2 2019 Aug 13, 2019	SELL	$113.99 - $146.86 $9,347 - $12,042	-82 Reduced 2.27%	3,526 $437,000
Q1 2019 May 06, 2019	BUY	$122.82 - $151.83 $443,134 - $547,802	3,608 New	3,608 $476,000

212

45.1M

106K

93.1K

Ticker BGNE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 103,700,000
Market Cap $23.3B
Description
BeiGene, Ltd., a biotechnology company, focuses on discovering, developing, manufacturing, and commercializing various medicines worldwide. Its products include BRUKINSA to treat relapsed/refractory (R/R) mantle cell lymphoma; Tislelizumab to treat R/R classical Hodgkin's lymphoma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplas...

Get notified when there are updates to the investment portfolio of American International Group, Inc., based on Form 13F filings with the SEC.

Stay updated on American International Group, Inc. with notifications on news.